dc.contributor.author | BROWN, SARA JUDITH | en |
dc.date.accessioned | 2011-11-16T11:21:49Z | |
dc.date.available | 2011-11-16T11:21:49Z | |
dc.date.issued | 2012 | en |
dc.date.submitted | 2012 | en |
dc.identifier.citation | Brown SJ, Kroboth K, Sandilands A, Campbell LE, Pohler E, Kezic S, Cordell HJ, McLean WH, Irvine AD., Intragenic Copy Number Variation within Filaggrin Contributes to the Risk of Atopic Dermatitis with a Dose-Dependent Effect, Journal of Investigative Dermatology, 132, 2012, 98 104 | en |
dc.identifier.other | Y | en |
dc.description | PUBLISHED | en |
dc.description.abstract | Loss-of-function variants within the filaggrin gene (FLG) increase the risk of atopic dermatitis. FLG also demonstrates intragenic copy number variation (CNV), with alleles encoding 10, 11, or 12 filaggrin monomers; hence, CNV may affect the amount of filaggrin expressed in the epidermis. A total of 876 Irish pediatric atopic dermatitis cases were compared with 928 population controls to test the hypothesis that CNV within FLG affects the risk of atopic dermatitis independently of FLG-null mutations. Cases and controls were screened for CNV and common FLG-null mutations. In this population the 11-repeat allele was most prevalent (allele frequency 51.5%); the 10-repeat allele frequency was 33.9% and the 12-repeat allele frequency was 14.6%. Having excluded FLG mutation carriers, the control group had a significantly higher number of repeats than cases (?2 P=0.043), and the odds ratio of disease was reduced by a factor of 0.88 (95% confidence interval 0.78?0.98, P=0.025) for each additional unit of copy number. Breakdown products of filaggrin were quantified in tape-stripped stratum corneum from 31 atopic dermatitis patients and urocanic acid showed a positive correlation with total copy number. CNV within FLG makes a significant, dose-dependent contribution to atopic dermatitis risk, and therefore treatments to increase filaggrin expression may have therapeutic utility. | en |
dc.description.sponsorship | This work was supported by a Wellcome Trust Intermediate Clinical Fellowship (ref 086398/Z/08/Z) awarded to SJB; filaggrin research in the McLean laboratory is supported by grants from the British Skin Foundation, National Eczema Society, Medical Research Council (ref G0700314), the Wellcome Trust (references 090066/B/09/Z and 092530/Z/10/Z), and donations from anonymous families affected by eczema in the Tayside Region of Scotland; SJB, SK, WHIM, and ADI are members of COST Action BM 0903 (Skin Barrier and Atopic Disease (SkinBAD)); HJC is supported by a Wellcome Trust Senior Fellowship (ref 087436); ADI has received funding from the National Children's Research Centre, Dublin, and the Wellcome Trust (references 090066/B/09/Z and 092530/Z/10/Z). We are very grateful to our patients who participated in this research and for the expert help of Mrs Nuala Aylward. We also thank Dr Grainne O?Regan for allowing us to utilize previously published data on filaggrin breakdown products quantified in tape-stripped stratum corneum. | en |
dc.format.extent | 98 104 | en |
dc.language.iso | en | en |
dc.relation.ispartofseries | Journal of Investigative Dermatology | en |
dc.relation.ispartofseries | 132 | en |
dc.rights | Y | en |
dc.subject | Clinical medicine | en |
dc.subject | Dermatology | en |
dc.subject | filaggrin gene (FLG) | en |
dc.title | Intragenic Copy Number Variation within Filaggrin Contributes to the Risk of Atopic Dermatitis with a Dose-Dependent Effect | en |
dc.type | Journal Article | en |
dc.type.supercollection | scholarly_publications | en |
dc.type.supercollection | refereed_publications | en |
dc.identifier.peoplefinderurl | http://people.tcd.ie/brownsj | en |
dc.identifier.rssinternalid | 75853 | en |
dc.identifier.rssuri | http://dx.doi.org/10.1038/jid.2011.342 | en |
dc.contributor.sponsor | Wellcome Trust | en |
dc.contributor.sponsorGrantNumber | 086398/Z/08/Z | en |
dc.identifier.uri | http://hdl.handle.net/2262/60718 | |